Fisetin in Mild Alzheimer's Disease

Recruiting Phase 2 Interventional Study
Alzheimer s Disease Alzheimer Dementia Alzheimer Dementia (AD) Alzheimer Disease Mild Cognitive Disorder Neurocognitive Disorders, Mild Neurocognitive Disorder
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
60 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
5 (estimated)
Sponsor
Sunnybrook Health Sciences Centre · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia * Moca score of 11 or higher * Stable psychotropics and cognitive enhancing medications Exclusion Criteria: * Known hypersensitivity or allergy to fisetin * Presence of any medical condition, or …
Contacts

Study Coordinator

416-480-6100

memoryresearch@sunnybrook.ca

CONTACT